http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#Head http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#assertion http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#provenance http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#pubinfo http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#assertion http://purl.obolibrary.org/obo/DOID_10322 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10322 http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00860 http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association http://www.w3.org/2000/01/rdf-schema#label prednisolone syrup prednisolone oral solution usp is indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus acute rheumatic carditis 4 dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis bronchial asthma contact dermatitis atopic dermatitis serum sickness drug hypersensitivity reactions 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia allergic conjunctivitis keratitis chorioretinitis optic neuritis iritis and iridocyclitis 7 respiratory diseases symptomatic sarcoidosis loeffler s syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy aspiration pneumonitis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood 1 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 12 miscellaneous tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement in addition to the above indications prednisolone syrup prednisolone oral solution usp is indicated for systemic dermatomyositis polymyositis http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00860 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#provenance http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#pubinfo http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#sig http://purl.org/nanopub/x/hasSignature Bzo7vF9ygBOy7V0SidtOaLf2otFXRHmDJMILLEoSQYVaSSlcCN8s6z46QETHUVq4pWHfmcFQMg0Fls4fZzQtykOmM0Sb+YJ0BzkQ45DJ77IlYEs9z/h5nCk+W4jqBmsiuFKrmKbUE67OzkdWclUD6WzDySqtci/6gh+GwGVDJ80= http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 http://purl.org/dc/terms/created 2021-06-18T09:29:38.502+02:00 http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAnkr4nTcBC8bDqSLtdVgC4Lpk_nmqKrYz0dZ8KXp6UL8 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs